Metilfenidato se salió del grupo .

Homonormado 🏳️‍🌈 Muy hater.

[Metilfenidato se salió del grupo . @MIPserable]

- ¿Padece alguna enfermedad crónica?
-No.
-¿Toma algún medicamento?
-Metformina, Lord-satan.

[Dr Rupam Manna MD @DrRupamOncology]

Endocrine Resistance in HR+ Breast Cancer: PI3K–AKT–mTOR Pathway & Targeted Therapies (2025–2026)

Understanding the mechanisms of endocrine resistance is critical for optimizing treatment in HR+ metastatic breast cancer.

This infographic covers:

• Key mechanisms driving resistance (PIK3CA, AKT1, PTEN alterations, ESR1 mutations)
• Current targeted therapy options: Capivasertib, Inavolisib, Alpelisib & Everolimus
• Biomarker-driven treatment selection
• Updated preferred sequencing in 2025–2026
• High-yield clinical pearls for exam and practice

A practical, evidence-based resource for medical oncologists, fellows, and residents.

Save this for your next HR+ breast cancer case.

#BreastCancer #EndocrineResistance #PI3K #AKT #mTOR #MedicalOncology #DrRupamManna

[D r. S u e ñ o @DrSleep88]

De verdad estamos en la puta mierda… ¿pero quién demonios consume este contenido? ¿Por qué se esmeran en ridiculizar nuestra profesión? ¿Hasta donde llegará 🇲🇽 en este mundial?

[Elvina Almuradova @Dr_ElvinaA]

Final 15-year SOFT/TEXT results confirm that ovarian function suppression matters in premenopausal HR+/HER2− early breast cancer.

•Tamoxifen + OFS reduces recurrence vs tamoxifen alone
•Exemestane + OFS further lowers recurrence and distant relapse risk
•Greatest benefit seen in very young women (<35 years) and other high-risk patients

A powerful reminder that treatment escalation should be considered for those at highest risk.
#BreastCancer @OncoAlert @oncodaily @Larvol

[Paolo Tarantino @PTarantinoMD]

This study deserved an oral presentation, btw

[Metilfenidato se salió del grupo . @MIPserable]

Adiós a mi extraño favorito.
Volveremos a ser extraños. Pero con memorias.

[Paolo Tarantino @PTarantinoMD]

Could an MRI after 12 weeks of neoadjuvant THP predict pCR?

Sub-analysis from CompassHER2pCR (~1400 pts) presented at #ASCO26

👉86% of ER-/HER2+ tumors with rCR on MRI actually had pCR
👉lower accuracy in ER+ disease, with 60% adequately predicted

Provides rationale to start with neoadjuvant THP and escalate with T-DXd if no MRI response among patients with stage II ER-/HER2+ disease

[Janira Navarro @Janiranavarro]

***Lepidic pattern is not limited to primary lung tumors***

- Female patient with history of breast cancer now with lung lesion (pic 1 and 2): Mesothelioma, epithelioid type
- Melanoma (pic 3)
- Cholangiocarcinoma (pic 3)

Practical lession: Lung tumors that looks like carcinoma but negative for TTF-1 and p40, add Claudin 4 and WT-1 to exclude the possibility of mesothelioma

Dr. Sauter #USCAP2026 #pathology #PathX #PathTwitter

[Syed Z. Ali @sza_jhcyto]

"A crowd may offer cover, but it rarely grants invisibility." Small Cell Carcinoma trying to blend in with ciliated bronchial cells. (Lung, Bronch Brush)

[Elizabeth Montgomery, MD @LizMontgomeryMD]

Horrible treatment (radiation) associated epithelial changes in duodenal mucosa. The p53 can be ignored, probably reflecting upregulation rather thana mutational event. The same can be seen in the stomach.
Hutchings DA, et al PMID: 36843539; PMCID: PMC10460459.

[Manumanito @manumanito]

Wowers que el LEGO de la Sagrada Familia incluyeron los vitrales y los árboles del interior. Está enormísimo por un módico precio de 18mil bolas.

[Paolo Tarantino @PTarantinoMD]

Every ASCO has some hidden pearls. One that I had the luck to attend was a presentation by Gil Shamai on the discordance between AI prediction and standard path features — wonderfully discussed by David Rimm. Highly recommended.

“AI errors are not bugs, but rather features”

[Dr Kamlesh Darji @DrKamleshDarji1]

Topic 14: Cells of chronic inflammation - 14/100 #Pathology #NEETPG

[Raza Hoda, MD @RazaHoda]

Metastatic Squamous Cell Carcinoma 🕵️🔬

Not every sentinel lymph node metastasis originates from breast. Here, metastatic squamous cell carcinoma from a primary cutaneous lesion of the ipsilateral arm was identified within a sentinel lymph node.

#PathX #PathTwitter #breastpath

[Felipe Templo Jr. ,MD, MBA 🕊 @thejourneymate]

Mucin Stains Explained 🔬

(c): Dr Rakesh Kumar

[Oren Gottfried, MD @OGdukeneurosurg]

Arteries and Veins

[Paolo Tarantino @PTarantinoMD]

The tremendous impact of endocrine Tx in the maintenance setting for ER+/HER2+ MBC. Even in the presence of tucatinib and HP you see a difference of 15 MONTHS in PFS depending on whether maintenance ET was utilized. These tumors often have luminal biology. Never forget ET!!!

[Orlando RPN @OrlandoRPN]

El Cáncer de Páncreas, por si no sabían, acabó con la vida de:

Steve Jobs
Alan Rickman (Severus Snape de Harry Potter)
Pavarotti
Umberto Eco
Patrick Swayze (ahora sí es Ghost la sombra del amor)

[Dr Rishabh Jain @DrRishabhOnco]

#ASCO26 🚨 ASCENT-03 reinforces the case for frontline sacituzumab govitecan in PD-L1–ineligible mTNBC.

Despite heavy crossover (82% of chemo arm later received SG), SG still improved PFS2:

🔹 PFS2: 18.2 vs 14.0 mo
🔹 HR 0.70
🔹 30% lower risk of progression after next-line therapy

Patients receiving upfront SG also had:
⏳ Longer TFST: 11.2 vs 7.9 mo
⏳ Longer TSST: 17.3 vs 16.6 mo

Key message:
Using SG earlier may provide more durable disease control rather than “saving it for later.”

@OncoAlert @myesmo @asco @esmo_open @GileadSciences
#BreastCancer #TNBC #OncoTwitter

[NEJM @NEJM]

Original Article: Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer (phase 3 RASolute 302 trial) https://t.co/y4G27hfORg

#ASCO26 | @ASCO